Trial Profile
A phase I study of therapy with the farnesyl transferase inhibitor R115777 (Zarnestra) combined with conventional induction and consolidation chemotherapy for previously untreated patients over age 55 with acute myeloid leukemia (AML).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is now 1 Jun 2008.